(MedPage Today) — And what will GOP do after expected veto of Obamacare “repeal bill”?
Category: News
Access to harm reduction programs vey low in rural and suburban areas affected by HIV infections
Access to harm reduction programs such as syringe exchange is lowest in rural and suburban areas, where rates of addiction to heroin and other opioids are on the rise, according to a study led by researchers at the Icahn School of Medicine at Mount Sin…
NovaBay Declares Reverse Stock Split
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) (“NovaBay” or the “Company”), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that, pursuant to authorization provided by the Company’s stockholders at the Company’s December 11, 2015, special stockholder meeting, and in order to meet the continued listing standards of the NYSE MKT, the Company’s Board of
Expert: More Oversight Needed for Health Facility Safety
(MedPage Today) — Lucian Leape, MD, calls for an “FAA-like” federal agency
Case Challenge: Slowly Growing Eyelid Mass
This woman’s sharp-eyed children have noticed that the ‘bump’ near their mom’s eye is getting bigger. Medscape Dermatology
Mount Sinai scientists develop new tool to determine global role of microRNAs
As microRNA biology has been implicated in everything from the development of cancer to virus infections, a new tool developed by scientists at the Icahn School of Medicine at Mount Sinai holds tremendous potential to develop new therapies that involve…
Neural stimulation offers treatment for ‘dry eye’
Scientists have developed a device that electronically stimulates tear production, which will offer hope to sufferers of dry eye syndrome, one of the most common eye diseases in the world.
Spiking Drug Prices in Spotlight at Senate Hearing
(MedPage Today) — Regulation, expedited review for competitors suggested
New heart failure drug may increase patients’ risk of Alzheimer’s disease, macular degeneration
Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug — a tablet that combines the agents valsartan and sacubitril, sold und…
Is seeing believing? People are not good at identifying where sights, sounds originate
Study by UCLA psychologists reveals that our senses are far from flawless.Our vision and hearing aren’t as reliable as we might think, according to a study by life scientists at UCLA.
Ophthalmologists Have Low Patient Complaint Rates
Ophthalmologists at academic centers have the highest risk for patient complaints compared with others in their field, but ophthalmology overall enjoys fewer complaints than other medical specialties. Medscape Medical News
AMD: Aflibercept Clinical Practice Efficacy Similar to Trials
Bimonthly administration may reduce the treatment burden and improve adherence, but longer-term visual acuity outcomes are still not known. Medscape Medical News
ACCORDION CV Mortality Drops, Eye Benefits Remain in Follow-up
New data from ACCORD long-term follow-up study: cardiovascular mortality risk with tight glycemic control attenuates, retinopathy benefit remains, and brain function unaffected. Medscape Medical News
New portable sensor can measure vitamin C levels in fluids that leak from the eye
An engineer and an ophthalmologist are developing a portable sensor that can quickly and inexpensively determine whether an eye injury is mild or severe. The device, called OcuCheck, measures levels of vitamin C in the fluids that coat or leak from the…
CardioBrief: More Safety Concerns on New HF Drug
(MedPage Today) — Potential for macular degeneration adds to Alzheimer’s disease worries with Entresto
Ignyta Announces Initiation of STARTRK “Next Generation” Phase 1/1b Pediatric Clinical Trial of Entrectinib
SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the initiation of STARTRK-NG, a new pediatric Phase 1/1b clinical trial of entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK. STARTRK-NG (which stands for “Studies of Tumor Alterations Responsive to Targeting Receptor Kinases – Next Generation”) is a multicenter, open
Portable device can quickly determine the extent of an eye injury
An engineer and an ophthalmologist are developing a portable sensor that can quickly and inexpensively determine whether an eye injury is mild or severe.
Why focusing on a visual task will make us deaf to our surroundings
Concentrating attention on a visual task can render you momentarily ‘deaf’ to sounds at normal levels, reports a new UCL study funded by the Wellcome Trust.
Roche announces regulatory clearance to finalize acquisition of Kapa Biosystems
Roche today announced regulatory clearance to finalize acquisition of Kapa Biosystems, Inc., a privately-held company headquartered in Wilmington, Massachusetts, US.
Reticare_USA to Exhibit at 2016 International CES, booth #36511, LVCC-SOUTH HALL 4
TAMPA, Fla.–(BUSINESS WIRE)–Reticare the world leader in eye protection from high energy light will show case two new innovative products at CES 2016 — Reticare Glasses and Reticare Glass.